Cell Senescence and the SASP

Introduction to Cellular Senescence

Cellular senescence is a stable, essentially irreversible cell cycle arrest state arising in response to diverse stresses—oncogene activation, telomere shortening, DNA damage, oxidative stress, inflammatory cytokines, tissue damage, replicative exhaustion, and developmental cues. Senescence was first described by Leonard Hayflick who observed that normal human diploid fibroblasts in culture ceased dividing after 40-60 population doublings (the Hayflick limit) without dying—a fundamental departure from the then-dominant assumption that cells could divide indefinitely. We now understand that replicative senescence results from telomere shortening to critical length triggering a permanent DNA damage response (DDR) signal at chromosome ends.

Senescence is paradoxical: it is tumour suppressive (preventing proliferation of potentially oncogenic cells) and developmentally beneficial (transient senescence sculpts embryonic tissue through paracrine signalling and immune-mediated clearance) but progressively harmful when senescent cells accumulate in aged tissues and are not efficiently cleared by the immune system—driving inflammation, fibrosis, stem cell niche impairment, and multiple age-related pathologies. This dual nature—beneficial acutely, harmful chronically—explains the evolutionary selection for senescence while contextualising why senescent cell accumulation in aged organisms is deleterious. Pharmacological senolytic drugs clearing accumulated senescent cells are entering clinical trials for multiple age-related diseases.

Induction of Cellular Senescence

Oncogene-Induced Senescence

Oncogene-induced senescence (OIS) is triggered by oncogenic RAS (HRASG12V), BRAF (BRAFV600E), and other mitogenic oncogenes whose excessive stimulation creates hyperproliferative signals that paradoxically arrest cells rather than driving unlimited growth. Manuel Serrano demonstrated that oncogenic H-RAS induced premature senescence in normal human and mouse fibroblasts—and that p53 or p16INK4a/Rb pathway disruption was required for oncogenic transformation instead of arrest. This established OIS as a tumour suppression mechanism in vivo. Benign melanocytic naevi (moles) are senescent BRAFV600E melanocyte colonies that have arrested—remaining as harmless lesions for decades; p16INK4a expression is universally high in naevus cells. When additional mutations disable p53 or bypass Rb (CDK4/6 activation), naevus cells escape senescence becoming melanoma.

Telomere-Dependent Replicative Senescence

Human telomeres are TTAGGG hexanucleotide repeats (5-15 kb at birth) added by telomerase (TERT-TERC-DKC1 reverse transcriptase complex)—constitutively expressed only in germ cells, stem cells, and most cancers, but silenced in most somatic cells. Each cell division erodes 50-200 bp from telomere ends (the end replication problem—DNA polymerase cannot replicate the 3' telomeric overhang) causing gradual shortening with each replication until critically short telomeres lose T-loop/G-quadruplex shelterin organisation generating persistent DDR signal (TRF2 loss from short telomeres exposes telomere ends to ATM/ATR recognition as double-strand breaks), triggering permanent p53-p21 and p16-Rb axis senescence arrest. Telomere length varies by cell type, tissue-specific replication history, and genetic factors—germline telomere length variants are associated with cancer risk, age-related morbidity, and longevity.

The Senescence-Associated Secretory Phenotype

SASP Composition and Regulation

The SASP (senescence-associated secretory phenotype) encompasses hundreds of secreted factors including: pro-inflammatory cytokines (IL-6—the dominant SASP cytokine, IL-8, IL-1alpha/beta); chemokines (CXCL1/2/5/8/10, CCL2/8/20) recruiting immune cells; matrix metalloproteinases (MMP1/3/9/10/13) remodelling ECM and processing growth factors and cytokines; growth factors (VEGF, HGF, FGF2, EGF) potentially promoting cancer growth; and non-coding RNAs including miR-21 and circRNAs in exosomes. SASP is regulated by NF-kappaB (p65, activated by DDR-mediated PARP/IKK signalling), C/EBP-beta, cGAS-STING (cytoplasmic DNA sensing from chromatin fragments escaping the nucleus during senescence), and PI3K-mTOR pathway (which regulates SASP gene translation). p38 MAPK and the NLRP3 inflammasome amplify the SASP in late senescence.

Senolytics and Senomorphics

Senolytics selectively eliminate senescent cells by targeting pro-survival pathways that senescent cells are uniquely dependent on for their persistence (SCAPs—senescent cell anti-apoptotic pathways). Dasatinib (BCR-ABL/Src inhibitor) + quercetin (flavonoid PI3K/MDM2/Bcl-xL inhibitor) combination was identified the first senolytic regimen in 2015—transiently administering D+Q every few weeks reduced senescent cell burden in aged mice improving physical function, cardiovascular health, and longevity. Navitoclax (ABT-263, BCL-2/BCL-xL/BCL-w inhibitor) is a potent senolytic—but causes thrombocytopenia from platelet dependence on BCL-XL, limiting clinical doses. UBX0101 (MDM2 inhibitor), fisetin, and piperlongumine are additional candidate senolytics. Senomorphics—drugs inhibiting SASP without killing senescent cells (JAK inhibitors, NF-kappaB inhibitors, mTOR inhibitors)—reduce SASP-driven inflammation without eliminating senescent cells themselves.

Examples and Applications

Example 1: p16INK4a as a Senescence Biomarker

p16INK4a (CDKN2A gene product) is the most widely used senescence biomarker—its expression is near-zero in young tissues, accumulates with ageing, and is elevated in senescent cells of all types. p16INK4a inhibits CDK4/6 preventing Rb phosphorylation, blocking E2F-driven S-phase entry. A transgenic mouse line expressing luciferase under the p16INK4a promoter enabled real-time imaging of senescent cell accumulation with age—clusters appearing in fat depots, periepididymal adipose, and lymph nodes years before affecting other tissues. p16 mRNA in peripheral blood T cells measured by PCR increases with chronological age and with accelerated physiological ageing (HIV infection, obesity, smoking), serving as a biological age surrogate in clinical cohort studies. In human skin biopsies, p16-positive cell density increases with UV exposure, smoking, and chronological age.

Example 2: Senescence in Embryonic Development

Transient senescence plays essential roles in embryonic tissue remodelling—distinct from pathological chronic senescence in that developmental senescent cells are rapidly cleared by macrophages. Senescent cells are observed in the endolymphatic sac, mesonephros, limb apical ectodermal ridge (AER), and intersomitic boundaries during window periods in mouse embryogenesis—their disruption by p21 deletion or BCL-2 overexpression (preventing senolysis) causes developmental abnormalities confirming their non-redundant function. Senescent cells in AER are cleared by macrophage infiltration during the typical AER regression phase; impaired macrophage-mediated clearance causes AER persistence and interdigital webbing—similar to developmental defects seen in some syndactyly conditions. Understanding developmental senescence mechanisms versus pathological senescence may enable distinction of beneficial from deleterious senescent cell populations for targeted elimination.

Example 3: Senescence in Wound Healing

Acute senescence is beneficial in wound healing: transiently senescent fibroblasts and myofibroblasts in healing wounds secrete PDGF-AA promoting myofibroblast differentiation and wound contraction; they are subsequently cleared by immune cells as wounds resolve. Pdgfa-senescence-reporter cell ablation in healing mice impairs wound closure, directly demonstrating pro-repair function of acute wound senescence. However, in chronic diabetic wounds, inflammatory senescent cells persist—not cleared by impaired macrophage function—contributing to chronic wound inflammation and impaired healing. Selective elimination of chronic senescent cells in diabetic wound beds using topical ABT-262 or navitoclax nanoparticle formulations showed accelerated wound closure in mouse models. These data explain why brief beneficial senescence and chronic pathological senescence represent distinct targets requiring selective temporal interventions.

Example 4: Senescence and IPF

Idiopathic pulmonary fibrosis (IPF) shows high senescent cell burden, particularly in alveolar type II (ATII) cells and fibroblasts. ATII cell telomere shortening (driven by telomerase mutations in familial IPF and age-related shortening in sporadic cases) triggers replicative senescence impairing alveolar regeneration and driving maladaptive TGF-beta SASP-mediated fibroblast activation. Navitoclax (ABT-263) treatment in telomere-associated IPF mouse models reduced ATII cell senescent burden and improved lung function. First-in-human Phase I trial (the RESOLVE study, 2021-2023) testing navitoclax transiently in IPF patients demonstrated feasibility, biomarker evidence of senolytic activity (reduced p21, p16 circulating markers), and preliminary suggestion of lung function stabilisation. UNITY Biotechnology and Senolytic Therapeutics lead clinical-stage senolytic development programmes for pulmonary, renal, and musculoskeletal applications.

Example 5: Senescence and the Tumor Microenvironment

Therapy-induced senescence (TIS)—senescence triggered in cancer cells and stromal cells by chemotherapy or radiation at sublethal doses—has paradoxical pro- and anti-tumour effects. If senescent cancer cells are not cleared, the pro-tumourigenic SASP (VEGF, IL-6, IL-8, MMPs, EGF) may promote growth of nearby cancer cells that escaped senescence—potentially accelerating relapse. CDK4/6 inhibitors (used clinically in ER+ breast cancer) induce senescence in breast cancer cells while supressing SASP through CDK4/6-dependent SASP gene translation. Sequential senolytic therapy administered after standard-of-care chemotherapy could eliminate TIS cancer cells before their SASP promotes recurrence—a 'One-Two Punch' strategy (first senescence induction, then senolysis) preclinically validated and being evaluated clinically in sequential combination trials.

Example 6: Progeroid Syndromes and Accelerated Senescence

Progeroid syndromes are rare genetic diseases causing premature ageing phenotypes—accelerated cellular senescence from genomic instability or telomere biology defects. Hutchinson-Gilford Progeria Syndrome (HGPS, LMNA c.1824C>T, causing progerin—a cryptic splice product truncating lamin A) causes nuclear lamina instability impairing DNA damage repair, inducing massive premature senescence and atherosclerosis—death from MI or stroke at median 14.6 years. Lonafarnib (FTI-farnesyltransferase inhibitor)—approved for HGPS in 2020—reduces accumulation of farnesylated progerin, improving vascular disease and extending life expectancy. Werner syndrome (WRN helicase mutations)—adult-onset progeroid syndrome with accelerated replicative senescence—reveals DNA helicase function in delaying senescence. These monogenic models of accelerated ageing validate the link between genomic maintenance, senescence, and ageing-related disease.

Example 7: Senolytics in Osteoarthritis

Osteoarthritis (OA) joint cartilage shows senescent chondrocyte accumulation—driven by oxidative stress, mechanical overload, and crystal deposition—all causing p53/p21 and p16/Rb activation. SASP from senescent chondrocytes (including MMP13, IL-6, CXCL1) directly degrades cartilage matrix and drives synovial inflammation. Injection of senescent cells into mouse knee joints caused OA features within weeks; conversely, clearing senescent cells with navitoclax or dasatinib+quercetin intra-articular injection reduced cartilage degradation and pain-related behaviours in OA mouse models. UNITY Biotechnology Phase II trial in knee OA patients with intra-articular UBX0101 showed marginal cartilage and pain improvement—insufficient for registration, driving in search of more potent senolytics or combination approaches. Senomorphic JAK inhibition with baricitinib showed cartilage-protective effects in OA animal models through SASP reduction.

Example 8: Biological Clocks and Epigenetic Ageing

Epigenetic clocks—mathematical models predicting biological age from DNA methylation patterns at specific CpG sites—provide biological age measurements that diverge from chronological age, predicting morbidity and mortality risk. Steve Horvath's DNAm-based pan-tissue clock (2013) using 353 CpG sites predicts chronological age with median absolute error of 3.6 years across diverse tissues; Hannum clock, PhenoAge, GrimAge, and DunedinPACE pace-of-ageing estimator provide refined clocks correlating with specific disease and mortality outcomes. Biological clock acceleration (epigenetic age older than chronological age) is caused by: smoking, obesity, high-stress environments, severe childhood adversity, HIV infection, and cancer. Caloric restriction, exercise, and certain interventions can decelerate biological clock. David Sinclair's group showed partial epigenetic reprogramming using Yamanaka factors cyclically expressed in aged mice partially reversed epigenetic age and improved retinal function, connecting epigenetic clock with rejuvenation biology.

Try it live

Everything above runs in your browser — open Cell Senescence & SASP Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.